ELIGARD KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ELIGARD KIT (ELIGARD KIT).
Leuprolide acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH). It acts as a potent inhibitor of gonadotropin secretion when administered continuously. After initial stimulation, chronic administration suppresses pituitary gonadotropin release, leading to reduced testicular and ovarian steroidogenesis.
| Metabolism | Primarily metabolized by peptidases in the liver and kidneys; no significant cytochrome P450 involvement. Approximately 50% of the dose is excreted unchanged in urine. |
| Excretion | Renal: negligible; Biliary/fecal: ~100% (metabolites); Unchanged drug: <5% in urine. |
| Half-life | Terminal elimination half-life: 25-30 days (due to slow release from depot). Clinical context: continuous suppression of LH/FSH requires monthly dosing. |
| Protein binding | 43% bound to albumin; negligible binding to sex hormone-binding globulin (SHBG). |
| Volume of Distribution | 10-20 L/kg (approx 15 L/kg). Clinical meaning: extensive distribution into tissues, including prostate, due to lipophilic nature. |
| Bioavailability | Subcutaneous: ~45-50% (due to slow release from polymer formulation); absolute bioavailability not established due to lack of IV formulation. |
| Onset of Action | Subcutaneous: Serum testosterone levels fall to castrate range (<50 ng/dL) within 2-4 weeks after first dose; initial transient flare (increase) in first few days. |
| Duration of Action | Single dose: maintains castrate testosterone levels for at least 1 month (28 days). Clinical notes: duration sufficient for monthly administration; testosterone suppression persists until next dose. |
| Molecular Weight | 1209.4 |
Subcutaneous injection of 7.5 mg (one kit) every month, or 22.5 mg every 3 months, or 30 mg every 4 months, or 45 mg every 6 months.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment recommended based on Child-Pugh class; however, monitor liver function as leuprolide is metabolized hepatically. |
| Pediatric use | Safety and efficacy not established; not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended for elderly patients; use standard adult dosing. |
| 1st trimester | Leuprolide acetate is contraindicated in pregnancy due to risk of fetal harm. It may cause pregnancy loss or fetal malformations. Use only if clearly needed with reliable contraception. |
| 2nd trimester | Same as t1. Leuprolide is contraindicated in pregnancy. Exposure during organogenesis may cause fetal anomalies. |
| 3rd trimester | Same as t1. Leuprolide should not be used during pregnancy. Consider alternative therapies. |
Clinical note
Comprehensive clinical and safety monograph for ELIGARD KIT (ELIGARD KIT).
| Placental transfer | Leuprolide undergoes placental transfer in animal studies. There are no human data; however, due to its molecular size and lipophilicity, placental transfer is expected. |
| Breastfeeding | Leuprolide is excreted in breast milk in low amounts. Due to potential for serious adverse reactions in nursing infants (e.g., hormonal effects), breastfeeding is not recommended during treatment and for at least 2 months after the last dose. |
■ FDA Black Box Warning
Leuprolide acetate is not indicated for use in women who are or may become pregnant. It may cause fetal harm when administered to a pregnant woman. Major birth defects and developmental abnormalities have been observed in animal studies.
| Serious Effects |
Hypersensitivity to leuprolide or any component of the formulationPregnancyUndiagnosed vaginal bleedingUse in women who are breastfeeding (relative contraindication; absolute if nursing infants are at risk)
| Precautions | Tumor flare: transient increase in serum testosterone during first weeks of therapy may cause worsening of prostate cancer symptoms (e.g., bone pain, urinary obstruction)., Hyperglycemia and increased risk of diabetes in men receiving GnRH agonists., Cardiovascular risk: increased risk of myocardial infarction, sudden cardiac death, and stroke., QT interval prolongation may occur; use with caution in patients with electrolyte abnormalities, congestive heart failure, or those taking QT-prolonging drugs., Seizures have been reported in patients with seizure disorders or risk factors., Hypersensitivity reactions including anaphylaxis., Bone density loss with prolonged use., Pituitary apoplexy, especially in patients with pituitary adenomas. |
Loading safety data…
| Lactation Rating | L4 |
| Teratogenic Risk | Eligard (leuprolide acetate) is contraindicated in pregnancy. Leuprolide is a GnRH agonist that can cause fetal harm when administered to a pregnant woman. First trimester exposure may increase risk of spontaneous abortion and congenital malformations due to hormonal disruption. In the second and third trimesters, there is potential for feminization of male fetuses and other adverse effects on fetal development. Adequate contraception must be used during treatment. |
| Fetal Monitoring | Pregnancy test should be performed prior to initiation of therapy to rule out pregnancy. If used inadvertently during pregnancy, the patient should be apprised of the potential hazard to the fetus. Monitoring for signs of pregnancy and fetal development is recommended if exposure occurs. |
| Fertility Effects | Leuprolide suppresses pituitary gonadotropin secretion, leading to ovarian suppression and reduced fertility during treatment. After discontinuation, fertility may return, but prolonged use can delay return of menses and ovulation. In females, amenorrhea is common; reversible upon treatment cessation. |
| Food/Dietary |
| No significant food interactions. Maintain a balanced diet; alcohol may exacerbate hot flashes. |
| Clinical Pearls | Eligard (leuprolide acetate) is a GnRH agonist for advanced prostate cancer. Initial testosterone flare can worsen symptoms; coadminister an antiandrogen for the first 2-4 weeks. Monitor liver function and cardiac risk factors. Suspend therapy if spinal cord compression or urinary obstruction develops. |
| Patient Advice | This drug will lower your testosterone levels, which can cause hot flashes, decreased libido, and erectile dysfunction. · You may experience a temporary worsening of prostate cancer symptoms during the first few weeks of treatment. · Take your injection exactly as scheduled; do not miss doses. · Report any new or worsening bone pain, difficulty urinating, or weakness in your legs immediately. · You will need regular blood tests to monitor your response and side effects. |